|
|
|
|
|
|
|
|
|
|
|
|
|
<PAGE> 1
EXHIBIT 99(b)
MERCK & CO., INC.
PRODUCT SALES DETAIL
<TABLE>
<CAPTION>
3Q `00 vs. 3Q `99
TOTAL TOTAL U.S. U.S. Foreign Foreign
PRODUCT % CHG $ % CHG $ % CHG $
<S> <C> <C> <C> <C> <C> <C>
VIOXX N/M $615 N/M $495 N/M $120
VASOTEC / VASERETIC -5% 460 21% 205 -19% 255
PRINIVIL / PRINZIDE 34% 295 36% 265 20% 30
COZAAR / HYZAAR 16% 405 6% 175 24% 230
MEVACOR 17% 135 29% 110 -17% 25
ZOCOR 18% 1,360 27% 905 3% 455
AGGRASTAT 75% 35 67% 25 100% 10
SINGULAIR 81% 235 90% 190 50% 45
MAXALT 80% 45 75% 35 100% 10
PROPECIA 11% 50 25% 25 0% 25
PROSCAR 9% 120 30% 65 -8% 55
PRIMAXIN 0% 140 -11% 40 5% 100
PEPCID -16% 190 -13% 175 -40% 15
FOSAMAX 29% 360 33% 260 18% 100
CRIXIVAN/STOCRIN -18% 140 -23% 50 -14% 90
TIMOPTIC/TIMOPTIC XE -14% 60 -40% 15 0% 45
TRUSOPT/COSOPT 13% 90 13% 45 13% 45
HEPATITIS VACCINES 31% 105 36% 95 N/M 10
VIRAL VACCINES 0% 155 4% 145 N/M 10
OTHER VACCINES N/M 20 N/M 10 N/M 10
</TABLE>
NOTE: Product sales rounded to the nearest $5 million.
N / M - Not Meaningful
<PAGE> 2
EXHIBIT 99(b)
MERCK & CO., INC.
PRODUCT SALES DETAIL
<TABLE>
<CAPTION>
9 MONTHS YTD 2000 OVER 1999
TOTAL TOTAL U.S. U.S. Foreign Foreign
PRODUCT % CHG $ % CHG $ % CHG $
<S> <C> <C> <C> <C> <C> <C>
VIOXX N/M $1,460 N/M $1,175 N/M $285
VASOTEC / VASERETIC -15% 1,460 -12% 640 -17% 820
PRINIVIL / PRINZIDE 34% 835 36% 750 13% 85
COZAAR / HYZAAR 22% 1,185 15% 505 27% 680
MEVACOR -15% 395 -15% 320 -17% 75
ZOCOR 19% 3,820 31% 2,440 2% 1,380
AGGRASTAT 82% 100 67% 75 N/M 25
SINGULAIR 86% 615 92% 480 69% 135
MAXALT 108% 135 110% 105 100% 30
PROPECIA 11% 150 0% 70 23% 80
PROSCAR 6% 345 18% 165 -3% 180
PRIMAXIN 7% 450 4% 130 8% 320
PEPCID -10% 610 -8% 555 -21% 55
FOSAMAX 27% 960 33% 670 16% 290
CRIXIVAN/STOCRIN -17% 410 -23% 155 -14% 255
TIMOPTIC/TIMOPTIC XE -10% 190 -23% 50 -3% 140
TRUSOPT/COSOPT 15% 265 14% 125 17% 140
HEPATITIS VACCINES 20% 270 23% 245 0% 25
VIRAL VACCINES 7% 405 7% 380 N/M 25
OTHER VACCINES N/M 50 N/M 30 N/M 20
</TABLE>
NOTE: In-line product sales rounded to the nearest $5 million.
N / M - Not Meaningful
<PAGE> 3
EXHIBIT 99(b)
MERCK & CO., INC.
THIRD QUARTER
<TABLE>
<CAPTION>
3Q `00 3Q `99 % CHG.
<S> <C> <C> <C>
TOTAL SALES $ 10,567.5 $ 8,195.7 29%
---------- ---------
TOTAL COSTS, EXPENSES, & OTHER $ 7,925.8 $ 5,961.0
---------- ---------
Materials & Production 5,952.5 4,365.9
Marketing & Administrative 1,512.8 1,272.7
Research & Development 609.8 516.0
Acquired Research - 51.1
Equity Income From Affiliates (219.4) (227.1)
Other (Income)/Expense, Net 70.1 (17.6)
PRE-TAX INCOME $ 2,641.7 $ 2,234.7
TAXES $ 805.7 $ 695.1
TAX RATE 30.5% 31.1%
NET INCOME $ 1,836.0 $ 1,539.6 19%
EPS - ASSUMING DILUTION $0.78 $0.64 22%
AVG. # SHARES - ASSUMING DILUTION 2,342.9 2,394.4
</TABLE>
<TABLE>
<CAPTION>
3Q `00 % CHG. VOL PX FX
<S> <C> <C> <C> <C> <C>
TOTAL SALES $10,570 29% 25 4 0
------- --- -- -- --
Total U.S. and Foreign Sales 5,170 18% 21 -2 -1
------- --- -- -- --
U.S. 3,345 23% 25 -2 0
Foreign 1,825 9% 13 -2 -2
Other Medco Sales 5,400 42%
</TABLE>
<PAGE> 4
EXHIBIT 99(b)
MERCK & CO., INC.
NINE MONTHS YEAR TO DATE
<TABLE>
<CAPTION>
2000 1999 % CHG.
<S> <C> <C> <C>
TOTAL SALES $ 28,895.9 $ 23,750.6 22%
------------ ------------ ---
TOTAL COSTS, EXPENSES, & OTHER $ 21,582.9 $ 17,342.5
------------ ------------
Materials & Production 15,872.9 12,890.2
Marketing & Administrative 4,393.5 3,611.3
Research & Development 1,681.5 1,440.5
Acquired Research -- 51.1
Equity Income From Affiliates (619.5) (581.5)
Other (Income)/Expense, Net 254.5 (69.1)
PRE-TAX INCOME $ 7,313.0 $ 6,408.1
TAXES $ 2,255.7 $ 2,090.8
TAX RATE 30.8% 32.6%
NET INCOME $ 5,057.3 $ 4,317.3 17%
EPS - ASSUMING DILUTION $2.15 $1.79 20%
AVG. # SHARES - ASSUMING DILUTION 2,351.6 2,410.1
</TABLE>
<TABLE>
<CAPTION>
9 mos `00 % CHG. VOL PX FX
<S> <C> <C> <C> <C> <C>
TOTAL SALES $28,895 22% 18 4 0
------- --- -- -- --
Total U.S. and Foreign Sales 14,820 18% 21 -2 -1
------- --- -- -- --
U.S. 9,430 24% 26 -2 0
Foreign 5,390 8% 11 -1 -2
Other Medco Sales 14,075 26%
</TABLE>
<PAGE> 5
EXHIBIT 99 (b)
MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
THIRD QUARTER
2000
OTHER (INCOME)/EXPENSE, NET
<TABLE>
<CAPTION>
3Q `00 3Q `99 9 mos '00 9 mos '99
<S> <C> <C> <C> <C>
INTEREST INCOME $(124.8) $(95.2) $(326.4) $(264.1)
INTEREST EXPENSE 121.8 79.0 355.1 219.3
EXCHANGE (GAINS)/LOSSES (14.3) (20.9) (31.8) (18.8)
MINORITY INTERESTS 74.8 61.8 230.8 168.5
AMORTIZATION OF GOODWILL AND INTANGIBLES 80.8 77.8 238.2 239.0
Other, net (68.2) (120.1) (211.4) (413.0)
------- ------ ------- -------
TOTAL $ 70.1 $(17.6) $ 254.5 $ (69.1)
</TABLE>
JOINT VENTURE SALES DETAIL
All sales reported here are end-market JV sales, presented on a "NET" basis,
rounded to the nearest $5 million.
<TABLE>
<CAPTION>
Merial 3Q `00 3Q `99 9 mos '00 9 mos '99
<S> <C> <C> <C> <C>
IVOMEC, HEARTGARD, other avermectins $ 150 $ 180 $ 405 $ 430
FRONTLINE 90 110 275 270
Biologicals 80 85 240 250
Other Animal Health 50 55 150 165
Poultry Genetics 55 50 165 175
------ ------ ------ ------
TOTAL MERIAL SALES $ 425 $ 480 $1,235 $1,290
</TABLE>
<TABLE>
<CAPTION>
PM-MSD 3Q `00 3Q `99 9 mos '00 9 mos '99
<S> <C> <C> <C> <C>
HEPATITIS VACCINES $ 35 $ 40 $110 $120
VIRAL VACCINES 10 15 35 50
Other Vaccines 125 120 260 245
---- ---- ---- ----
TOTAL PM-MSD SALES $170 $175 $405 $415
</TABLE>
TOTAL MEDCO PRESCRIPTION/CLAIMS VOLUME (in millions)
<TABLE>
<CAPTION>
2000 1999 % Chg
<S> <C> <C> <C>
FIRST QUARTER 99 94 5%
SECOND QUARTER 98 91 8%
THIRD QUARTER 120 90 33%
--- --- --
YEAR TO DATE 317 275 15%
</TABLE>
|
|